Marimed Inc

Good morning. My name is Pam and I will be your conference operator today. At this time, I would like to welcome everyone to the Miramed third quarter 2022 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question at any time, simply press star then the number one on your telephone keypad. If you would like to withdraw your question, please press star followed by two. Thank you. I would now like to turn the conference call over to Mr. Steve West, Vice President of Investor Relations. Please go ahead.

Good morning, everyone, and welcome to Merrimed's third quarter 2022 conference call. Joining me on the call today are Bob Fireman, our Chief Executive Officer, John Levine, our President, Tim Shaw, our Chief Operating Officer, and Susan Valera, our Chief Financial Officer. This call is being recorded and will be archived on our investor relations website at ir.merrimetinc.com. Today's call contains forward-looking statements subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from those forward-looking statements. These risks and uncertainties are discussed in our documents filed with the SEC, including our most recent Form 10-K and Form 10-Q. Any forward-looking statements reflect management's expectations as of today's date and we assume no obligation to update them other than as may be required by applicable securities laws. In addition, we will present non-GAAP financial information on this call. Reconciliations to applicable GAAP financial measures are included in our earnings release as well as in the supplemental slides which are available on our investor relations website. For your future scheduling purposes, Our fourth quarter 2022 earnings release is tentatively scheduled to be issued after the market closes on March 1st, 2023, and our subsequent analyst call will be held the morning of March 2nd, 2023. I will now turn the call over to Bob.

Thank you, Steve, and good morning, everyone. I am pleased to report that Merrimet had another solid quarter of financial growth and operational results. Our revenue continues to increase both year over year and quarter over quarter. Most importantly, we are reporting positive adjusted EBITDA for the 11th consecutive quarter. We continue to successfully execute on our strategic growth plan during the third quarter, advancing several significant milestones. These milestones include assets and resources to further increase our company's revenue and earnings. We are pleased that we are outperforming our competitors in terms of sales growth in all our key markets. The headwinds of inflation from COVID, the war in Ukraine, the price compression have not taken Merrimack off our course. This is a result of the quality of our products and services, as well as the culture and excellence of our team. We are hopeful that President Biden's new cannabis policy statement and other initiatives at the federal level will improve capital markets access to U.S. cannabis companies to list on senior exchanges. This will allow more institutional investors to participate in our success. Maramed is poised to continue to grow up to $400 million dollars in revenue in the next few years. As one of the few MSOs with a clean balance sheet, operational excellence, strong financial discipline, and is profitable, we are well positioned as a transformational M&A participant. Rest assured, any transaction seriously considered must be accretive and improve Merrimack shareholder value. I suggest you all keep watching the Merrimack story. Let me now turn it over to John. Thank you.